Patents Examined by Cherie M. Woodward
-
Patent number: 8110210Abstract: A biocompatible meniscal repair device is disclosed. The tissue repair device includes a scaffold adapted to be placed in contact with a defect in a meniscus, the scaffold comprising a high-density, dry laid nonwoven polymeric material and a biocompatible foam. The scaffold provides increased suture pull-out strength.Type: GrantFiled: April 20, 2004Date of Patent: February 7, 2012Assignee: DePuy Mitek, Inc.Inventors: Stephanie M. Kladakis, Joseph J. Hammer, Dhanuraj Shetty, Sridevi Dhanaraj
-
Patent number: 8110664Abstract: A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.Type: GrantFiled: November 28, 2003Date of Patent: February 7, 2012Assignee: RSR LimitedInventors: Jane Sanders, Jadwiga Furmaniak, Bernard Rees Smith
-
Patent number: 8105621Abstract: A biocompatible meniscal repair device is disclosed. The tissue repair device includes a scaffold adapted to be placed in contact with a defect in a meniscus, the scaffold comprising a high-density, dry laid nonwoven polymeric material and a biocompatible foam. The scaffold provides increased suture pull-out strength.Type: GrantFiled: June 29, 2006Date of Patent: January 31, 2012Assignee: DePuy Mitek, Inc.Inventors: Sridevi Dhanaraj, Stephanie M. Kladakis, Joseph J. Hammer, Dhanuraj Shetty, Mark Timmer
-
Patent number: 8101736Abstract: An isolated polypeptide comprising, contiguously, a first amino acid sequence being at least 90% homologous to amino acid coordinates 1-398 of SEQ ID NO: 2, a tryptophan residue and a second amino acid sequence being at least 90% homologous to amino acid coordinates 400-523 of SEQ ID NO:2. Also provided are polynucleotide sequences encoding this polypeptide and uses of same in the treatment of medical conditions associated with ion channel insufficiency.Type: GrantFiled: December 12, 2006Date of Patent: January 24, 2012Assignee: GeneGrafts Ltd.Inventors: Tal Bresler, Yair Feld, Reem Miari, Lior Gepstein, Shimon Marom
-
Patent number: 8097581Abstract: The present invention relates to a composition for treating skin comprising an acylated short chain bioactive peptide and fulvic acid, and optionally colloidal gold. The invention further relates to a method for topically administering the composition in an amount therapeutically effective to reduce wrinkles by building the dermal fibroblast matrix. The invention further relates to a method of treating wrinkled skin by topically administering the composition to an individual in need of such treatment.Type: GrantFiled: May 12, 2008Date of Patent: January 17, 2012Assignee: Grant Industries Inc.Inventors: Amit R. Shah, John L. Gormley, George P. Majewski
-
Patent number: 8093007Abstract: The present invention provides a method for analyzing agonist-activity to a cytokinin receptor, which comprises (1) bringing an examinee substance into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced and (2) measuring the existence or the quantity of intracellular signal transduction from the cytokinin receptor expressed in the transformed cell, and, a method for analyzing antagonist activity to a cytokinin receptor, which comprises (1) bringing an examinee substance and a substance having agonist-activity to the cytokinin receptor into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced and (2) measuring the existence or the quantity of intracellular signal transduction from the cytokinin receptor expressed in the transformed cell, and the like.Type: GrantFiled: May 4, 2010Date of Patent: January 10, 2012Assignee: Sumitomo Chemical Company, LimitedInventors: Tatsuo Kakimoto, Masayuki Higuchi, Tsutomu Inoue
-
Patent number: 8075934Abstract: The present invention is directed an improved nutritional composition, methods of improving digestion, and methods of enhancing the bioavailability of TGF-?.Type: GrantFiled: February 13, 2009Date of Patent: December 13, 2011Assignee: Mead Johnson Nutrition CompanyInventors: Dattatreya Banavara, Win-Chin Chiang, Deborah A. Schade, Joaquin A. Franco, Juan M. Gonzalez, Dirk Hondmann, Zeina E. Jouni, Yung-Hsiung Lee, Robert J. McMahon, Kristin Morris, Deshanie Rai, Gyan P. Rai, Nagendra Rangavajla, Francisco J. Rosales, William Michael Russell, Eric Van Tol, Hugh N. Tucker, Donald Carey Walker
-
Patent number: 8071124Abstract: Liquid, injectable, aqueous solutions are transformed in situ to an expandable foam-like, space filling, and adherent biomaterial. Preferably, the foam-like biomaterial is the reaction product of a two-part liquid system to achieve the in situ formation thereof. The liquid system is generally comprised of a protein solution and a cross linker solution which may either be premixed and then applied to a site in need of the biomaterial, or simultaneously mixed and delivered through an in-line mixing/dispensing tip directly to the site. In especially preferred embodiments, an expandable foam-like biomaterial includes the reaction product of human or animal-derived protein material and a di- or polyaldehyde in the presence of a bicarbonate and an acidic titrant amounts sufficient to impart a cellular foam structure to the material.Type: GrantFiled: January 26, 2005Date of Patent: December 6, 2011Assignee: CryoLife, Inc.Inventors: K. Umit Yuksel, Ana T. Bird, Kirby S. Black
-
Patent number: 8067155Abstract: Methods for detecting phosphorylation of receptor tyrosine kinases (“RTKs”) upon activation are provided. The method employs cells comprising two fusion products: (1) an RTK fused to a small fragment of ?-galactosidase and (2) a phosphotyrosine binding peptide fused to the large fragment of ?-galactosidase, where the 2 fragments weakly complex to form an active enzyme, and optionally a construct for a cytosolic RTK phosphorylating kinase, when the RTK does not autophosphoryate. To detect phosphorylation a ?-galactosidase substrate is added to the cells, whereby product formation indicates the occurrence of phosphorylation.Type: GrantFiled: August 6, 2009Date of Patent: November 29, 2011Assignee: DiscoveRx CorporationInventors: Wei Feng, William Raab, Philip Achacoso, Thomas Wehrman, Keith R. Olson
-
Patent number: 8062350Abstract: Provided herein is a method of using a bioabsorbable medical device that includes RGD attached to the device via a spacer compound. The method comprises implanting in a human being a bioaborbable device, e.g., a bioabsorbable stent, including a chemo-attractant for endothelial progenitor cells (EPCs).Type: GrantFiled: February 21, 2008Date of Patent: November 22, 2011Assignee: Abbott Cardiovascular Systems Inc.Inventors: David C. Gale, Bin Huang, Kleine Klaus
-
Patent number: 8062677Abstract: Provided herein are compositions for the administration of chromium that include at least two components: a hydrophilic chromium complex and a lipophilic chromium complex, and methods of using the same. Also provided are compositions for the administration of chromium that include a first “fast-acting” chromium complex and a second “slow-acting” chromium complex, wherein the first chromium complex is absorbed more quickly than the slow-acting chromium complex, and methods of using the same. Also provided herein are methods for treating, preventing, and improving conditions associated with cardiometabolic syndrome, by identifying a subject in need of treatment, prevention, or improvement of a condition associated with cardiometabolic syndrome, and providing a therapeutically effective amount of a composition comprising a fast-acting chromium complex and a slow-acting chromium complex, to the individual.Type: GrantFiled: December 19, 2008Date of Patent: November 22, 2011Assignee: Nutrition 21, Inc.Inventor: James R. Komorowski
-
Patent number: 8062640Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.Type: GrantFiled: December 15, 2009Date of Patent: November 22, 2011Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T Huang, Douglas MacDonald
-
Patent number: 8058021Abstract: An improved monocyte activation test is described that is better able to detect non-endotoxin pyrogens in medical products, in which a sample is incubated with a monocyte-containing reagent in an assay system comprising at least one surface comprising polypropylene. The invention also concerns assay systems for use in these tests that include at least one microtiter well having at least one interior surface comprising polypropylene and having a shape such that monocyte-containing reagent is concentrated in the well to provide greater cell to cell contact. The invention also relates to a diagnostic kit that can be used to test for the presence of non-endotoxin pyrogens in a sample.Type: GrantFiled: April 26, 2010Date of Patent: November 15, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A., National Institute for Biological Standards and ControlInventors: Stephen Poole, Mehul Patel
-
Patent number: 8057818Abstract: Liquid, injectable, aqueous solutions are transformed in situ to an expandable foam-like, space filling, and adherent biomaterial. Preferably, the foam-like biomaterial is the reaction product of a two-part liquid system to achieve the in situ formation thereof. The liquid system is generally comprised of a protein solution and a cross linker solution which may either be premixed and then applied to a site in need of the biomaterial, or simultaneously mixed and delivered through an in-line mixing/dispensing tip directly to the site. In especially preferred embodiments, an expandable foam-like biomaterial includes the reaction product of human or animal-derived protein material and a di- or polyaldehyde in the presence of a bicarbonate and an acidic titrant amounts sufficient to impart a cellular foam structure to the material.Type: GrantFiled: January 26, 2005Date of Patent: November 15, 2011Assignee: CryoLife, Inc.Inventors: K. Umit Yüksel, Ana T. Bird, Kirby S. Black
-
Patent number: 8053200Abstract: An improved monocyte activation test is described that is better able to detect non-endotoxin pyrogens in medical products, in which a sample is incubated with a monocyte-containing reagent in an assay system comprising at least one surface comprising polypropylene. The invention also concerns assay systems for use in these tests that include at least one microtiter well having at least one interior surface comprising polypropylene and having a shape such that monocyte-containing reagent is concentrated in the well to provide greater cell to cell contact. The invention also relates to a diagnostic kit that can be used to test for the presence of non-endotoxin pyrogens in a sample.Type: GrantFiled: April 26, 2010Date of Patent: November 8, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A., National Institute for Biological Standards and ControlInventors: Stephen Poole, Mehul Patel
-
Patent number: 8048414Abstract: F(ab) fragments are isolated from an antibody containing source by contacting the antibody containing source with a papain-polyacrylamide matrix to produce F(ab) and F(c) fragments which are then passed through an antigen-polyacrylamide gel capable of attracting the F(ab) fragments. F(ab)2 fragments are obtained by contacting the antibody containing source with a pepsin-polyacrylamide matrix to produce F(ab)2 and F(c) fragments which are then passed through an antigen-polyacrylamide gel capable of attracting the F(ab)2 fragments. IgG antibodies are obtained by passing an antibody containing source through an antigen-polyacrylamide gel. These processes can be used to purify a wide variety of antibodies which can be used as therapeutic agents and as diagnostic agents. Antivenins produced by these processes have substantially reduced foreign protein levels and hence are less likely to produce immunogenic reactions.Type: GrantFiled: March 15, 1995Date of Patent: November 1, 2011Assignee: BTG International Inc.Inventors: John B. Sullivan, Findlay E. Russell
-
Patent number: 8048847Abstract: This invention relates to the use of the IL-2 common gamma (c?c) and related molecules for the modulation of signal activities controlled by NIK, and some new such molecules.Type: GrantFiled: July 1, 2008Date of Patent: November 1, 2011Assignee: Yeda Research and Development Co., Ltd.Inventors: David Wallach, Parameswaran Ramakrishnan, Taisia Shmushkovich
-
Patent number: 8034763Abstract: The invention provides a pharmaceutical composition comprising at least one polypeptide of the following (a) to (d): (a) a polypeptide comprising the amino acid sequence of SEQ ID NO:1; (b) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (a) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity; (c) a polypeptide comprising the amino acid sequence of SEQ ID NO:3; and (d) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (c) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity, as an active component.Type: GrantFiled: November 2, 2006Date of Patent: October 11, 2011Assignees: Educational Foundation Jichi Medical University, Otsuka Pharmaceutical Co., Ltd.Inventors: Shigeto Yoshida, Toshiki Sudo
-
Patent number: 8029813Abstract: Concentrated microemulsions comprising: 1) 10-25 parts by weight of a pesticide with a solubility in water 20° C. lower than 1% by weight and having a melting point from 10° C. to 60° C.; 2) 8-25 parts by weight of one or more solvents containing oxygen atoms, having a solubility in water at 20° C. lower than 5% by weight and the Hildebrand solubility parameter in the range 16-21 MPa1/2: 3) 10-20 parts by weight of a polyol; 4) 10-25 parts by weight of one or more non ionic surfactants having a HLB value from 9 to 15; 5) 2-10 parts by weight of one or more anionic surfactants: 6) water up to 100 parts by weight; wherein—the ratio by weight between 2) and 1) ranges from 0.8:1 to 1.5:1;—the ratio by weight between 4)+5) and 1) is in the range 0.5:1-3:1;—the ratio by weight between 4) and 5) ranges from 1:1 to 4.1.Type: GrantFiled: February 26, 2004Date of Patent: October 4, 2011Assignee: Sipcam S.p.A.Inventors: Marco Bernardini, Francesca Borgo, Luigi Capuzzi, Pietro Domenichini, Giorgio Freschi
-
Patent number: 8022037Abstract: A wound healing composition comprising an amount of heat shock protein effective to promote wound healing and a method thereof to apply the composition. A preferred heat shock protein is either full-length hsp90? or the middle domain plus the charged sequence of hsp90?. The composition is topically applied to skin wounds, covering the outer surface of the wound. The heat shock protein acts by promoting migration of both human epidermal keratinocyte and dermal fibroblasts to the wound in order to close, heal, and remodel the wound.Type: GrantFiled: January 8, 2008Date of Patent: September 20, 2011Assignee: University of Southern CaliforniaInventors: Wei Li, Mei Chen, David T. Woodley